Accelerating the Drug Delivery Pipeline for Acute and Chronic Pancreatitis: Knowledge Gaps and Research Opportunities
Acute and chronic pancreatitis account for 300,000+ hospital admissions per year, effect large healthcare expenditures for inpatient and outpatient treatment, and result in a high risk of metabolic and neoplastic diseases.
No effective drugs are currently available to halt progression or effect the reversal of acute and chronic pancreatitis.
- To identify the requirements, obstacles and opportunities to enhance the development and clinical testing of potential therapeutic agents for the treatment of acute pancreatitis, recurrent acute pancreatitis and chronic pancreatitis
- To identify research gaps which are needed to facilitate drug development and clinical testing
- To engage representatives from the Food and Drug Administration to assist with the development of guidance documents which will assist investigators in studies of the treatment of these diseases
Additional support from the National Pancreas Foundation
July 11, 2018